基石藥業-B(02616.HK)與LCB就抗體偶聯藥物LCB71訂立授權協議
格隆匯 10 月 29日丨基石藥業-B(02616.HK)發佈公告,2020年10月28日,公司與LegoChem Biosciences, Inc.(“LCB”或“許可方”)訂立授權協議,據此,許可方授予獨家許可以允許公司(“被許可方”)於韓國境外地區開發並商業化LCB71,一種以受體酪氨酸激酶樣孤兒受體1(“ROR1”)為靶點的臨牀前階段抗體偶聯藥物(“ADC”)。
根據授權協議並按照其中的條款及條件,許可方有權就開發、監管及商業里程碑收取總額為1000萬美元的預付款及總額為3.535億美元的或然付款。此外,許可方有權收取基於LCB71淨銷售額的分層特許權使用費。籤立授權協議後,公司將負責承擔於韓國境外地區LCB71所有正在進行的以及未來試驗有關的開發和監管事務相關活動的所有費用。根據授權協議,公司須遵守慣常的排他性不競爭義務,而許可方和被許可方須遵守慣常的相互陳述、保證、契約和彌償保證。
ROR1在多種癌症中都有高表達,包括各類白血病、非霍奇金淋巴瘤、乳腺癌、肺癌及卵巢癌。LCB71具有專有的腫瘤激活的吡咯並苯二氮卓(“PBD”)前毒素,可解決與傳統PBD載荷有關的典型毒性問題。LCB71已在幾種臨牀前癌症模型中證明具有完全的腫瘤抑制作用,這或將會轉化為多種實體和血液惡性腫瘤的廣泛治療指標。此外,LCB71利用定向偶聯技術獲得精準的藥物抗體比率,有效地支持藥物血清半衰期並改善其藥代動力學特性,也便於實現均質生產及大規模生產。公司確信與LCB訂立的授權協議以新模式加強了基石的精準治療產品管線,並通過在新興及具備巨大發展潛力的ADC領域中取得這款潛在的同類首創╱ 同類最優資產的全球性權利,推進其管線2.0戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.